Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Once-daily oral ICP-332 therapy has demonstrated notable efficacy and a favorable safety profile in the treatment of patients with 

Jinhua Xu, PhD, of Fudan University’s Huashan Hospital in Shanghai, authored this paper alongside a team of other investigators, and it was published in 

. Xu and coauthors set out to assess ICP-332, a tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe atopic dermatitis.

This oral small-molecule TYK2 inhibitor was formulated to selectively bind to the TYK2 catalytic domain JH1. The drug can help to block signal transduction of inflammatory cytokines among patients.

 It was evaluted by the investigators in this new, phase 2 study.

“Herein, we evaluate the safety and efficacy of ICP-332 in patients with moderate to severe [atopic dermatitis] in a double-blind, placebo-controlled phase 2 randomized clinical trial,” Xu and colleagues wrote.

Xu et al’s phase 2 randomized clinical trial implemented a double-blind, placebo-controlled, multi-center design, with their research being conducted across 19 clinical sites within China. The study took place between February - November 2023. A screening phase was included during the protocol, lasting up to 35 days. This was followed by a 4-week double-blind treatment period and then a safety follow-up period lasting 28 days.

Adults between 18 - 75 years of age were considered eligible if they had a documented history of atopic dermatitis for a single year minimum prior to the initial dose of ICP-332. The diagnosis of this condition was confirmed at the time of patient screening via the Williams criteria. Subjects were required, to qualify as having moderate to severe disease, to have an Eczema Area and Severity Index (EASI) score of 16 or greater. They would also have to show involvement of at least 10% of body surface area as well as a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 3 or greater at the point of baseline.

Race and ethnicity were self-identified by participants and collected to explore whether these factors influenced treatment outcomes. Eligible individuals also needed a documented inadequate response to topical corticosteroids or topical calcineurin inhibitors, defined as use for a minimum of 4 weeks within the year prior to screening, or a clinical reason that made topical therapy inappropriate. To minimize confounding effects from prior therapies, use of Janus kinase inhibitors or other biologic agents within 12 weeks before the first dose was not permitted, and conventional systemic treatments were prohibited within 4 weeks of study entry.

In a 1:1:1 ratio, participants were randomly assigned to be treated with oral ICP-332 at a 80 mg dose, at 120 mg, or placebo once-per-day for 4 weeks. The trial subjects and study investigators remained blinded to treatment allocation throughout the study’s double-blind period. Safety served as the analysis’s main endpoint. Xu and coauthors’ principal efficacy endpoint was the percentage change from baseline in participants’ EASI score at the 4-week mark. Among other efficacy assessments, the team also evaluated the proportion of participants attaining at least a 75% reduction in EASI (EASI-75) and the proportion achieving a vIGA-AD score of 0 (clear) or 1, with an improvement of at least 2 points from the point of baseline.

There were 75 patients recruited in Xu et al’s study. ICP-332 demonstrated a favorable safety profile among these patients, with most adverse events (AEs) classified as mild in their level of disease severity. There were no instances of death or any AEs considered to be serious taking place during the analysis. By the 4-week mark, mean placebo-adjusted EASI reductions from baseline were −61.6% for individuals on 80 mg of ICP-332 and −55.8% for those in the 120-mg dosing cohort. These findings indicated substantial disease severity improvements compared with placebo.

“In this phase 2 randomized clinical trial, ICP-332 monotherapy was efficacious and demonstrated a favorable benefit-risk profile compared with placebo in adults with moderate to severe [atopic dermatitis], supporting initiation of larger randomized, controlled, phase 3 studies to confirm its potential as an effective treatment for this population,” the team concluded.

Xu J, Zhang L, Liang Y, et al. Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis: A Phase 2 Randomized Clinical Trial. JAMA Dermatol. Published online January 14, 2026. 

Brandt EB﻿, Sivaprasad U﻿. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):110. doi:10.4172/2155-9899.1000110.

Articles

Once-daily oral ICP-332 therapy has shown significant efficacy and a favorable safety profile in treating moderate to severe atopic dermatitis. Conducted across 19 clinical sites in China, the phase 2 double-blind, placebo-controlled trial involved 75 patients. Participants were randomly assigned to receive either 80 mg, 120 mg of ICP-332, or placebo. The primary endpoint was safety, while efficacy was measured by changes in EASI scores. Results indicated substantial improvements in disease severity, supporting further phase 3 trials to confirm its potential as an effective treatment.

Once-daily treatment of atopic dermatitis with oral ICP-332 showed a favorable safety profile and meaningful efficacy in a new study.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

ICP-332 Effective, Safe for Treating Moderate to Severe Atopic Dermatitis

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

 asthma and chronic obstructive pulmonary disease 

(COPD) management has undergone a steady but profound transformation, driven by deeper insight into disease heterogeneity and inflammatory pathways. What were once treated as largely uniform conditions managed through stepwise inhaler escalation are now understood as biologically diverse diseases requiring more individualized strategies. This shift has been fueled by advances in biomarker science, growing recognition of steroid-related harm, and the emergence of targeted biologic therapies capable of altering disease trajectories rather than simply relieving symptoms.

These new biologics, namely dupilumab in 2024 and mepolizumab in 2025, have begun to revolutionize the field of COPD, particularly eosinophilic COPD. With a growing variety of options, clinicians increasingly face nuanced decisions around patient selection, timing of initiation, response assessment, and long-term management—particularly as biologic options expand beyond asthma into select COPD populations. These developments have prompted a reexamination of long-standing treatment paradigms and renewed focus on outcomes such as exacerbation prevention, steroid reduction, and quality of life.

and led by MeiLan K. Han, MD, MS, Henry Sewall Professor of Medicine, Professor of Internal Medicine and Section Head, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, gathered expert perspectives to examine how these evolving tools are being integrated into real-world practice. Against a backdrop of rapid therapeutic progress, the discussion reflects a field in transition as clinicians adapt to a new era of precision-driven care for asthma and COPD.

Throughout the discussion, Han and the other participants stepped back to reflect on how biologics have reshaped the management of severe asthma, shifting care away from reactive symptom control toward proactive, inflammation-targeted intervention. They discussed how lessons learned with biologic management of asthma will need to be applied for COPD, with an emphasis on identifying appropriate candidates using clinical history and biomarkers, reassessing traditional definitions of disease severity, and recognizing the cumulative burden of exacerbations and chronic oral corticosteroid exposure. They also highlighted practical considerations such as timing of initiation, expectations for response, and strategies for evaluating effectiveness over time. Furthermore, more research and understanding about the overlap and differences between phenotypes across COPD and asthma is needed.

“My general take on it is that there are certain aspects that are the same, and it does appear that there are some drugs that are same, but there's many aspects to it. I think it is probably doing a little bit of a disservice to overgeneralize and to say, yeah, it's type 2 inflammation in COPD… I think there's a lot more nuance about what the triggers are, because if it wasn't, then the drugs would work exactly the same, right?” Han said.

Bringing biologics into COPD comes with its own challenges, especially in such as  historically heterogeneous and undertreated population. Integration into regular practice depends on careful patient selection, realistic outcome measures, and shared decision-making. Across both diseases, barriers such as access, insurance requirements, and workflow integration were acknowledged, alongside the growing need for clinician education as biologic therapies become a more routine component of chronic airway disease management. Despite these barriers, Han and other panelists remain excited about the future of COPD treatment.

“It's definitely exciting to maybe have something that would work not just in type 2 patients, but in everybody else. Because we've had a lot of carryover drugs from asthma, but it's kind of nice to see something that might be COPD specific,” Han commented on the potential of IL-33 targeting therapies for COPD.

Asthma and COPD management has evolved significantly, emphasizing individualized strategies due to insights into disease heterogeneity and inflammatory pathways. The introduction of biologics like dupilumab and mepolizumab has transformed treatment, particularly for eosinophilic COPD, prompting a reevaluation of traditional paradigms. A clinical forum led by Dr. MeiLan K. Han highlighted the integration of biologics into practice, focusing on patient selection, timing, and response assessment. Challenges include patient selection, outcome measures, and access barriers, but there is optimism about the future of COPD treatment with new therapies.

Experts discussed how biologics revolutionize asthma and COPD management, emphasizing personalized treatment strategies and proactive care.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

From GOLD to Ground Level: Navigating Biologic Use in COPD Care

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

New research suggests intravesical gentamicin administered at the time of ureteroneocystostomy may not reduce the incidence of urinary tract infections (UTIs) following

The findings indicate gentamicin may not be efficacious as infection prophylaxis against UTI-driving pathogens compared with no antibiotic irrigation, with investigators emphasizing clinicians should continue to individualize management based on patient-specific urine culture data.

“UTIs remain a frequent complication following kidney transplantation, and strategies to mitigate the risk of post-transplant UTIs continue to be highly sought after,” wrote study investigator Andrew Santeusanio, PharmD, BCPS, director of PGY-2 Solid Organ Transplant Residency at Mount Sinai Hospital, and colleagues.

Common urinary pathogens isolated after kidney transplantation include 

 species. To reduce UTI risk, clinicians may perform intraoperative antibiotic bladder irrigation during ureteroneocystostomy using agents targeting these organisms.

Gentamicin, a potent aminoglycoside antibiotic, is often used for infection prophylaxis. Prior studies have explored gentamicin bladder irrigation as a preventative strategy, though evidence regarding the efficacy of antibiotic bladder irrigation has remained conflicting.

To further evaluate this practice, investigators conducted a single-center retrospective cohort study using records from the Internal Transplant Institute to identify adult patients who underwent first isolated kidney transplantation. Outcomes were compared between patients who received bladder irrigation with a single dose of gentamicin 80 mg/2 mL and a control group who did not receive antibiotic irrigation. Maintenance immunosuppression consisted of tacrolimus for 3 months, in combination with mycophenolate and tapering corticosteroids based on immunologic risk.

The primary endpoint was the incidence of culture-confirmed UTI within 3 months of transplantation. Patients with a positive urine culture showing bacterial growth >10⁴ colony-forming units (CFUs) who received antibiotic treatment were considered to have met the primary endpoint. Key secondary endpoints included delayed allograft function, serum creatinine, culture-confirmed UTI >10⁵ CFUs, and acute rejection at 3 months.

The analysis included 764 adult patients aged ≥18 years, including 358 in the control group and 406 in the gentamicin group. The mean age of transplant recipients was 53.6 years, with most patients being male and representing diverse racial backgrounds.

Investigators reported no statistically significant differences between groups in induction or maintenance immunosuppression. However, significantly more patients in the control group required reoperation compared with the gentamicin group (4.2% vs 1.7%; 

At 3 months, graft survival was 98.8% among patients receiving gentamicin (n = 401) and 99.2% among control patients (n = 355). Overall, 121 patients (15.8%) developed a UTI within 3 months of transplantation.

For the primary endpoint, investigators observed an increased incidence of culture-confirmed UTI in the gentamicin group compared with the control group (18.2% vs 13.1%; 

 = .05). These differences were no longer statistically significant when analyses were restricted to organisms with >10⁵ CFUs (13.3% vs 10.1%; 

 = .16), organisms susceptible to gentamicin (16.7% vs 12.0%; 

 = .06), or infections occurring before ureteral stent removal (6.2% vs 3.1%; 

 = .06). Median time to first UTI was 28 days in the gentamicin group and 34 days in the control group, with freedom from UTI favoring the control group (

Analysis of secondary outcomes showed no significant differences between groups in delayed allograft function (23.4% vs 20.7%; 

 = .94), serum creatinine at 3 months (mean [SD], 1.5 [0.8] vs 1.5 [0.7]; 

 = .48). However, the gentamicin group had a higher incidence of BK viremia >10,000 IU/mL compared with controls (5.9% vs 2.5%; 

In multivariable analysis, investigators identified older age, female sex, treated acute rejection, longer dialysis vintage, and increased urinary catheter duration as independent risk factors for post-transplant UTIs.

After adjustment, intravesical gentamicin was no longer statistically associated with increased UTI risk (

 = .07). Factors that remained significantly associated with UTI risk included recipient age (relative risk [RR], 1.03 per decade), female sex (RR, 1.67), treated acute rejection (RR, 2.97), longer dialysis vintage (RR, 1.07 per year), and longer indwelling catheter duration (RR, 1.06 per day).

Although the findings suggest no added benefit from gentamicin bladder irrigation, investigators emphasized the importance of individualized prophylactic strategies.

“The choice of antibiotic prophylaxis should still be individualized based on culture data for patients with a history of UTIs or donors with a positive urine culture at the time of organ recovery,” investigators concluded.

Dean S, Santeusanio A, Patel G, Wadhera V, Shapiro R. Efficacy of a Single Dose of Intravesical Aminoglycoside for the Prevention of Urinary Tract Infections in Kidney Transplant Recipients. 

Harmon C, Hassoun A. Antibiotic Bladder Irrigation in Preventing and Reducing Chronic Urinary Catheter-Related Urinary Tract Infections (UTI). 

Gravetz A, Tennak V, Khamis M, et al. Evaluation of Intraoperative Gentamicin Bladder Irrigation for Mitigation of Urinary Tract Infections After Kidney Transplantation: A Propensity Score–Matched Analysis of a Randomized Controlled Trial. Hod-Dvorai R, ed. 

Recent research indicates that intravesical gentamicin administered during ureteroneocystostomy may not effectively reduce urinary tract infections (UTIs) post-kidney transplantation. The study compared outcomes between patients receiving gentamicin bladder irrigation and those without antibiotic irrigation, finding no significant difference in UTI incidence. Secondary outcomes, such as delayed allograft function and acute rejection, also showed no significant differences. However, gentamicin was associated with higher BK viremia incidence. The study emphasizes the need for individualized prophylactic strategies based on patient-specific urine culture data and risk factors.

A retrospective analysis does not link gentamicin with decreased risks of urinary tract infections after kidney transplantation.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Gentamicin May Not Reduce Post Kidney Transplant Urinary Tract Infection Risk 

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A recent study found that bronchodilator responsiveness was more strongly associated with progression to 

chronic obstructive pulmonary disease (COPD) 

and decline in forced expiratory volume in 1 second (FEV₁) than polygenic risk scores.

“In conclusion… [bronchodilator responsiveness] enhances the predictive ability of clinical models for COPD progression in [non-Hispanic White participants], whereas adding [polygenic risk scores] did not,” wrote study investigator Spyridon Fortis, MD, from the division of pulmonary, critical care, and occupational medicine at the University of Iowa Hospital and Clinics, and colleagues.

Bronchodilator responsiveness has been associated with lung function decline and progression to chronic obstructive pulmonary disease (COPD), although evidence is mixed regarding its ability to predict COPD development.

Polygenic risk scores (PRS) are known to predict reduced lung function and increased COPD risk.

Investigators aimed to determine whether genetic predisposition to COPD is associated with bronchodilator responsiveness and whether these factors independently or jointly influence lung function decline among individuals at risk for COPD.

To address these questions, the investigators conducted a cross-sectional analysis using data from 4,824 adults aged 45–80 years enrolled in the US-based, multicenter COPDGene study. All participants had a ≥10 pack-year smoking history and normal spirometry at baseline. The cohort included 1,446 African American and 3,378 non-Hispanic White participants.

Genetic risk was evaluated in relation to bronchodilator responsiveness, defined as the percent increase in forced expiratory volume in 1 second (FEV₁) following bronchodilator administration. Responsiveness was assessed using pre-bronchodilator lung function measured in 2005 and predicted lung function in 2021 as reference points.

The study revealed that genetic risk was not correlated with bronchodilator response in African American individuals (

 =.82) but had a slight, albeit weak, correlation in non-Hispanic White individuals (

 <.001). Non-Hispanic White participants with bronchodilator responsiveness exhibited a greater polygenic risk score than those without.

The team noted that prediction models that included bronchodilator responsiveness measured in 2005 were more accurate than models that included polygenic risk scores. This was true in both non-Hispanic White and African American participants, as shown by greater area under the curve (AUC) values in each group (AUC, 0.762 vs 0.743 for White participants (

 =.0004); 0.693 vs 0.653 for African Americans).

Additionally, among White participants, people whose lungs responded more strongly to a bronchodilator tended to experience faster declines in lung function over time. For example, a 10% greater bronchodilator response in 2005 was linked to losing 14.8 mL of lung volume per year, and a 10% higher response in 2021 was linked to losing about 18.3 mL per year. By comparison, a higher genetic risk score was associated with a much smaller decline of about 2.7 mL per year.

Models that included bronchodilator response explained the changes in lung function better than those using genetics alone. There was also some evidence that genetics and bronchodilator response together affected lung decline, but this was only seen for the 2005 measurements.

In mediation analyses, differences in bronchodilator responsiveness explained roughly one-third of the association between polygenic risk and long-term FEV₁ decline. However, no significant mediation was observed for acute bronchodilator-related changes in FEV₁, consistent with the lack of association between polygenic risk and bronchodilator responsiveness.

“…our findings suggest that while PRS and BDR may share biological pathways influencing FEV1 decline, they also capture distinct dimensions of COPD susceptibility—PRS reflecting inherited risk for impaired lung development and decline, and BDR reflecting airway responsiveness and inflammation,” investigators wrote. “These findings highlight that [bronchodilator responsiveness] captures airway disease processes beyond genetic susceptibility and remains a more robust predictor of COPD progression across populations.”

Fortis S, Comellas AP, Bowler RP, et al. Relationships between bronchodilator responsiveness, a COPD polygenic risk score, and COPD progression. 

Halpin DMG. Bronchodilator Responsiveness in Asthma and Chronic Obstructive Pulmonary Disease: Time to Stop Chasing Shadows. 

. 2024;209(4):349-351. doi:10.1164/rccm.202312-2248ED

Bronchodilator responsiveness (BDR) is a stronger predictor of COPD progression and FEV₁ decline than polygenic risk scores (PRS), particularly in non-Hispanic White individuals. A study involving 4,824 adults from the COPDGene study found that BDR was more predictive of lung function decline than PRS, with greater accuracy in prediction models. While PRS and BDR may share biological pathways, they capture distinct aspects of COPD susceptibility. BDR reflects airway responsiveness and inflammation, offering a more robust prediction of COPD progression across populations.

A study found that bronchodilator responsiveness more accurately forecasts FEV₁ decline and COPD development than polygenic risk scores.

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Jamie Scott, PhD, is an EiC senior chemist at the University of Edinburgh.

Advancing Noninvasive Diagnostics for Inflammatory Bowel Disease, With Jamie Scott, PhD

Despite its central role in inflammatory bowel disease (IBD) pathogenesis, clinicians have historically lacked a way to directly monitor T cell–driven immune activity, instead relying heavily on endoscopy, histology, and nonspecific inflammatory markers.

A novel GzmA activity-based optical assay developed by a team of University of Edinburgh researchers may have the potential to address this gap, accelerating the design of new biomedical approaches to enhance precision medicine in IBD. Their research offers the first non-invasive chemiluminescence assay measuring extracellular active GzmA in stool supernatants from human IBD patients, built using a combination of functional, chemical, and imaging assays in human cells and gut tissue biopsies from IBD patients.

“In the diagnosis and monitoring of IBD patients, there are a number of gaps,” Jamie Scott, PhD, an EiC senior chemist at the University of Edinburgh, told 

. If we focus on the gold standard, colonoscopy, we know that that is a particularly brutal way to assess patients. It's not pleasant, it's time consuming for healthcare systems, and depending on the area of the colon that's sampled, you may get results which do not reflect the true state of the immune system in the gut.”

With these shortcomings in mind, Scott points to the need for the development of noninvasive IBD technologies. By identifying a mechanistic, noninvasive biomarker that reflects adaptive immune activation in the gut, he says his team is hopeful that they have developed a tool that will more easily monitor and diagnose people with IBD.

In the research, investigators observed higher levels of GzmA in patients with active ulcerative colitis (UC) or active Crohn’s disease (CD) in inflamed tissues compared to non-inflamed regions from the same individuals. Because this enzyme is primarily released by CD8+ T cells to induce the secretion of the neutrophil chemoattractant IL-8 by monocytes, its active form serves as an indicator of T cell-mediated inflammation.

Investigators designed a GzmA activity-based chemiluminescence assay for testing clinical biosamples from IBD patients. To do this, they synthesized GzmA-CL as an GzmA-selective activatable chemiluminescent reporter with exceptional reactivity and kcat/KM values around 107 M-1 s-1. They then integrated both GzmA-CL and GzmA-INH into a 96-well plate assay to quantify the chemiluminescence readouts of multiple biosamples and examined stool supernatants from a cohort of IBD patients, including UC and CD patients as well as healthy controls.

Results revealed high levels of active GzmA in IBD patients, corroborating its role in gut inflammation, particularly in patients with highly active disease. While all healthy control samples displayed fecal calprotectin levels under the 50 mg kg-1 threshold, 38% of IBD patients displayed scores in the 50-200 mg kg-1 undefined region.

Of note, the combined analysis of active GzmA from T cells (adaptive) and fecal calprotectin from neutrophils (innate) enhanced monitoring of disease activity in IBD patients (95%) when compared to using fecal calprotectin scores alone (62% range).

“In order to move this technology further along the pipeline to commercialization, there would need to be some discussions with clinicians about what they want,” Scott explained, noting inherent limitations to the technology in its current form as well as the need for a powered statistical study on clinical samples to validate the findings from this pilot study.

Editors’ Note: The University of Edinburgh has filed a patent covering methods for granzyme detection, in which Scott is a named inventor.

 A chemiluminescence assay targeting granzyme A activity for monitoring inflammatory bowel disease. 

https://doi.org/10.1038/s41551-025-01588-1

University of Edinburgh. New test could help pinpoint IBD diagnosis, study finds. January 13, 2026. Accessed January 14, 2026. 

https://www.eurekalert.org/news-releases/1112281

Videos

Scott describes current unmet needs in IBD diagnosis and monitoring but points to the potential of a new GzmA activity-based optical assay.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Despite an OTC approval in 2023, recent data highlights a carry rate of only 10% in the general population.

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

FDA News

Family Medicine

Family Medicine condition center page, resources on the topics of medical news and expert insight into family care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Family medicine research, treatment, and drug development.

FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates

Roxana Mehran, MD, is a professor of medicine and director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Wiener Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai.

Mehran addresses roadblocks to inclusivity in new drug trials, emphasizing the need for a more diverse patient population for more broadly applicable evidence.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Making Cardiology Trials Work for Every Patient, With Roxana Mehran, MD

Global analysis links elevated BMI and low physical activity to rising hypertension-related chronic kidney disease burden, with deaths projected to increase through 2050.


Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Elevated BMI and Physical Inactivity Drive Rising Global Hypertension-CKD Burden

Both ethnicity and skin phototype were found in this analysis not to independently influence patients’ level of atopic dermatitis severity or their quality of life (QoL).

Pediatric Eczema Severity, Quality of Life Not Influenced by Phototype, Ethnicity

Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

This episode focuses on translating clinical evidence into everyday treatment decisions.

Video Series

Evolving Therapeutic Strategies and Real-World Application in IgAN

Analysis of > 9,000 FDA reports highlights previously unrecognized adverse events, including myocardial stunning, nerve damage, and real-world drug ineffectiveness.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

20 Years of FDA Data Reveal Previously Unrecognized Epinephrine Risks

The KDIGO 2025 guidelines update emphasizes a more aggressive approach to treating IgA Nephropathy.

2025 KDIGO Guideline Update for IgAN

Jennifer Manne-Goehler, MD, is a physician in the division of infectious diseases at Brigham and Women’s Hospital and the department of medicine at Mass General Brigham.

Manne-Goehler discusses a recent study highlighting the scope and scale at which GLP-1 receptor agonists can reduce obesity and its associated risks.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

1 in 4 Adults Worldwide Eligible for GLP-1 Treatment for Obesity, With Jennifer Manne-Goehler, MD

Investigators ranked the short-term effectiveness of 4 oral JAKis, upadacitinib, abrocitinib, baricitinib, and ivarmacitinib in moderate-to-severe atopic dermatitis.

Upadacitinib Outperforms 4 JAK Inhibitors in Atopic Dermatitis Meta-Analysis

CMTX-101 met safety endpoints in a phase 1b/2a cystic fibrosis study, with meaningful reductions in inflammatory biomarkers and pulmonary Pseudomonas aeruginosa burden.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Latest News

ICP-332 Effective, Safe for Treating Moderate to Severe Atopic Dermatitis

From GOLD to Ground Level: Navigating Biologic Use in COPD Care

Gentamicin May Not Reduce Post Kidney Transplant Urinary Tract Infection Risk

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Advancing Noninvasive Diagnostics for Inflammatory Bowel Disease, With Jamie Scott, PhD